Haisco Pharmaceutical Group Co Ltd
SZSE:002653

Watchlist Manager
Haisco Pharmaceutical Group Co Ltd Logo
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Watchlist
Price: 33.81 CNY 0.03% Market Closed
Market Cap: 37.9B CNY
Have any thoughts about
Haisco Pharmaceutical Group Co Ltd?
Write Note
Haisco Pharmaceutical Group Co Ltd
/
Income Statement
/
Interest Income Expense

Haisco Pharmaceutical Group Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Haisco Pharmaceutical Group Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Interest Income Expense
¥84.8m
CAGR 3-Years
-50%
CAGR 5-Years
59%
CAGR 10-Years
2%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
¥1.1B
CAGR 3-Years
52%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
¥145.3m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
¥472.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
¥958.5m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
-¥20.1m
CAGR 3-Years
-107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Haisco Pharmaceutical Group Co Ltd
Glance View

Market Cap
37.7B CNY
Industry
Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd. is an embodiment of relentless ambition and strategic foresight in China's burgeoning pharmaceutical landscape. Founded in 2000, the company quickly carved a niche for itself by focusing on the research, development, production, and sale of a diverse array of pharmaceutical products. Haisco's journey is rooted in an ethos of innovation and quality, as it sought to establish itself as a leader in the creation of anesthetics and antipyretic analgesics, among other critical therapeutic products. The company's prowess in research and development is clearly evident in its extensive pipeline and its state-of-the-art manufacturing facilities, which meet international standards. These capabilities allow Haisco to capture significant market share domestically and extend its reach into international markets. Where Haisco truly shines is in its operational model and financial acumen, driving its revenue streams through both business-to-business (B2B) and business-to-consumer (B2C) channels. On the B2B side, Haisco partners with hospitals, clinics, and other healthcare institutions to supply essential medications, ensuring a steady stream of revenue from bulk orders. Meanwhile, its direct-to-consumer sales strategy leverages in-depth market research to target retail pharmacies and end customers with a razor-sharp focus on effectiveness and affordability. By maintaining a dual-channel approach that capitalizes on economies of scale and robust distribution networks, Haisco not only amplifies its market penetration but also fortifies its financial performance. The company's strategic investments in technology and its commitment to stringent quality controls underpin its success, fostering trust and loyalty among consumers and partners alike.

Intrinsic Value
22.05 CNY
Overvaluation 35%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Haisco Pharmaceutical Group Co Ltd's Interest Income Expense?
Interest Income Expense
84.8m CNY

Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Interest Income Expense amounts to 84.8m CNY.

What is Haisco Pharmaceutical Group Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
2%

Over the last year, the Interest Income Expense growth was -51%. The average annual Interest Income Expense growth rates for Haisco Pharmaceutical Group Co Ltd have been -50% over the past three years , 59% over the past five years , and 2% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.